Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Desmond Curran

Showing results (31-40 of 85) with videos related to

Pageof 9
Sort By:
Human Vaccines & Immunotherapeutics|January 20, 2022
Modeled impact of the COVID-19 pandemic and associated reduction in adult vaccinations on herpes zoster in the United StatesDesmond Curran, Elizabeth M La, Ahmed Salem, et al.
Infectious Diseases and Therapy|November 2, 2022
Natural History of Herpes Zoster in the Placebo Groups of Three Randomized Phase III Clinical TrialsDesmond Curran, Sean Matthews, Céline Boutry, et al.
Clinical Interventions in Aging|August 26, 2022
An Easy-to-Implement Clinical-Trial Frailty Index Based on Accumulation of Deficits: Validation in Zoster Vaccine Clinical TrialsMelissa K Andrew, Sean Matthews, Joon Hyung Kim, et al.
BMC Health Services Research|April 25, 2025
Cost-effectiveness and public health impact of recombinant zoster vaccine versus no herpes zoster vaccination in selected populations of immunocompromised adults in CanadaSydney George, Justin Carrico, Katherine A Hicks, et al.
Human Vaccines & Immunotherapeutics|December 14, 2021
Long-term efficacy data for the recombinant zoster vaccine: impact on public health and cost effectiveness in GermanyDesmond Curran, Desirée Van Oorschot, Sean Matthews, et al.
BMJ Open|August 30, 2019
Herpes zoster related healthcare burden and costs in immunocompromised (IC) and IC-free populations in England: an observational retrospective database analysisDesmond Curran, Manjit Hunjan, Amale El Ghachi, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 26, 2026
Age-Specific Risk of Herpes Zoster in Adults Aged ≥18 Years With Comorbid Conditions-A Retrospective Cohort Study in the United StatesRachel A Cohen, Driss Oraichi, Agnes Mwakingwe-Omari, et al.
Human Vaccines & Immunotherapeutics|March 2, 2021
A systematic literature review of herpes zoster incidence worldwideDésirée van Oorschot, Hilde Vroling, Eveline Bunge, et al.
Open Forum Infectious Diseases|February 23, 2019
The Economic Burden and Impact on Quality of Life of Herpes Zoster and Postherpetic Neuralgia in Individuals Aged 50 Years or Older in ItalySean Matthews, Antonio De Maria, Marco Passamonti, et al.
Human Vaccines|May 1, 2010
Surveillance to estimate the burden of rotavirus gastroenteritis in children aged less than 3 years attending day care centers in Paris, FranceEmmanuel Grimprel, Antoine Garbarg-Chenon, Jean-Yves Pirçon, et al.
Pageof 9

Showing results (31-40 of 85) with videos related to

Sort By:
Pageof 9
Human Vaccines & Immunotherapeutics|January 20, 2022
Modeled impact of the COVID-19 pandemic and associated reduction in adult vaccinations on herpes zoster in the United StatesDesmond Curran, Elizabeth M La, Ahmed Salem, et al.
Infectious Diseases and Therapy|November 2, 2022
Natural History of Herpes Zoster in the Placebo Groups of Three Randomized Phase III Clinical TrialsDesmond Curran, Sean Matthews, Céline Boutry, et al.
Clinical Interventions in Aging|August 26, 2022
An Easy-to-Implement Clinical-Trial Frailty Index Based on Accumulation of Deficits: Validation in Zoster Vaccine Clinical TrialsMelissa K Andrew, Sean Matthews, Joon Hyung Kim, et al.
BMC Health Services Research|April 25, 2025
Cost-effectiveness and public health impact of recombinant zoster vaccine versus no herpes zoster vaccination in selected populations of immunocompromised adults in CanadaSydney George, Justin Carrico, Katherine A Hicks, et al.
Human Vaccines & Immunotherapeutics|December 14, 2021
Long-term efficacy data for the recombinant zoster vaccine: impact on public health and cost effectiveness in GermanyDesmond Curran, Desirée Van Oorschot, Sean Matthews, et al.
BMJ Open|August 30, 2019
Herpes zoster related healthcare burden and costs in immunocompromised (IC) and IC-free populations in England: an observational retrospective database analysisDesmond Curran, Manjit Hunjan, Amale El Ghachi, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 26, 2026
Age-Specific Risk of Herpes Zoster in Adults Aged ≥18 Years With Comorbid Conditions-A Retrospective Cohort Study in the United StatesRachel A Cohen, Driss Oraichi, Agnes Mwakingwe-Omari, et al.
Human Vaccines & Immunotherapeutics|March 2, 2021
A systematic literature review of herpes zoster incidence worldwideDésirée van Oorschot, Hilde Vroling, Eveline Bunge, et al.
Open Forum Infectious Diseases|February 23, 2019
The Economic Burden and Impact on Quality of Life of Herpes Zoster and Postherpetic Neuralgia in Individuals Aged 50 Years or Older in ItalySean Matthews, Antonio De Maria, Marco Passamonti, et al.
Human Vaccines|May 1, 2010
Surveillance to estimate the burden of rotavirus gastroenteritis in children aged less than 3 years attending day care centers in Paris, FranceEmmanuel Grimprel, Antoine Garbarg-Chenon, Jean-Yves Pirçon, et al.
Pageof 9